COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib

• Main Authors: Claudio Ucciferri, Antonio Auricchio, Stefano Marinari, Jacopo Vecchiet, Katia Falasca
• Format: Article
• Language: English
• Published: SAGE Publishing 2021-09-01
• Series: European Journal of Inflammation
• Online Access: https://doi.org/10.1177/20587392211036813

We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG). We chose Ruxolitinib, as a second-line treatment, after administering a standard therapy with hydroxychloroquine and lopinavir/ritonavir, due to a rapid deterioration in the patient’s lung function. Ruxolitinib is a janus kinase inibithor with selectivity for subtypes JAK1 and JAK2. A rapid improvement in the patient’s respiratory function, objectified with an increase in PO 2 /FiO 2 value, has been observed in the 10 days after the introduction of Ruxolitinib. Surprisingly we noticed a reduction in pulmonary fibrosis by comparing the chest- CT made before and after the COVID-19 diagnosis. JAK/STAT signalling is involved both in pathogenesis of the second part of COVID-19 and in the modulation of fibrosis in patients with SSc. The use of ruxolitinib should be a new therapeutic option in patients with COVID-19 and lung fibrosis.